Læknablaðið - apr. 2020, Síða 23

LÆKNAblaðið 2020/106 191
R A N N S Ó K N
með, virðist meðferðin einstaklingsmiðuð og helsta ábending
aðgerðar var versnun á sjónsviði þrátt fyrir lyfjameðferð. Meðal-
tal sjónsviðsskerðingar reyndist hærra í okkar rannsókn en í er-
lendum samanburðarrannsóknum og tæplega 80% augna höfðu
miðlungs eða alvarlega sjónsviðsskerðingu í viðkomandi auga.
Sjúklingar með alvarlega sjónsviðsskerðingu höfðu að meðaltali
lægri augnþrýsting og þynnri hornhimnu samanborið við sjúk-
linga með milda og miðlungsalvarlega sjónsviðsskerðingu. Þetta
getur bent til þess að mikil áhersla sé lögð á háan augnþrýsting
sem ábendingu fyrir aðgerðarþörf en ef til vill of lítil áhersla lögð
á sjónsviðsskerðingu, útlit sjóntaugar og þunna hornhimnu. Lágt
hlutfall augna með lágþrýstingsgláku kann að benda til hins sama.
Þessar niðurstöður benda til þess að sjúklingar með alvarlega sjón-
sviðsskerðingu gætu haft hag af því að undirgangast skurðaðgerð
fyrr með það að markmiði að hindra alvarlega og óafturkræfa sjón-
sviðsskerðingu.
Þakkir
Höfundar þakka vísindasjóði Landspítala fyrir veittan fjárstyrk til
rannsóknarinnar. Húnbogi Þorsteinsson fær þakkir fyrir yfirlestur
greinarinnar og góðar ábendingar.
Greinin barst til blaðsins 9. janúar 2020, samþykkt til birtingar 18. mars 2020.
1. Björnsson G. Prevalence and causes of blindness in
Iceland. With special reference to glaucoma simplex. Am J
Ophthalmol 1955; 39: 202-8.
2. Gunnlaugsdottir E, Arnarsson A, Jonasson F. Prevalence
and causes of visual impairment and blindness in
Icelanders aged 50 years and older: The Reykjavik Eye
Study. Acta Ophthalmol 2008; 86: 778-85.
3. Leske MC, Heijl A, Hyman L, Bengtsson B, Dong LM,
Yang Z. Predictors of long-term progression in the early
manifest glaucoma trial. Ophthalmology 2007; 114: 1965-
72.
4. Bertrand V, Fieuws S, Stalmans I, Zeyen T. Rates of
visual field loss before and after trabeculectomy. Acta
Ophthalmol 2014; 92: 116-20.
5. The Advanced Glaucoma Intervention Study (AGIS): 7.
The relationship between control of intraocular pressure
and visual field deterioration. The AGIS investigators. Am
J Ophthalmol 2000; 130: 429-40.
6. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B,
Hussein M, et al. Reduction of intraocular pressure and
glaucoma progression: results from the Early Manifest
Glaucoma Trial. Arch Ophthalmol 2002; 120: 1268-79.
7. The effectiveness of intraocular pressure reduction in
the treatment of normal-tension glaucoma. Collaborative
Normal-Tension Glaucoma Study Group. Am J
Ophthalmol 1998.
8. National Institute for Health and Care Excellence.
Glaucoma: diagnosis and management | Guidance and
guidelines | NICE. NICE NG81. 2017.
9. Boland MV, Ervin AM, Friedman DS, Jampel HD, Hawkins
BS, Vollenweider D, et al. Comparative effectiveness of
treatments for open-angle glaucoma: a systematic review
for the U.S. Preventive Services Task Force. Ann Intern
Med 2013; 158: 271-9.
10. Musch DC, Gillespie BW, Lichter PR, Niziol LM, Janz
NK; CIGTS Study Investigators. Visual field progression
in the Collaborative Initial Glaucoma Treatment Study
the impact of treatment and other baseline factors.
Ophthalmology 2009; 116: 200-7.
11. Foulsham WS, Fu L, Tatham AJ. Prior rates of visual
field loss and lifetime risk of blindness in glaucomatous
patients undergoing trabeculectomy. Eye (Lond) 2015; 29:
1353-9.
12. Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz
NK, Wren PA, et al. Interim clinical outcomes in the
Collaborative Initial Glaucoma Treatment Study compar-
ing initial treatment randomized to medications or sur-
gery. Ophthalmology 2001; 108: 1943-53.
13. European Glaucoma Society Terminology and Guidelines
for Glaucoma, 4th Edition - Chapter 3: Treatment princip-
les and options Supported by the EGS Foundation: Part 1:
Foreword; Introduction; Glossary; Chapter 3 Treatment
principles and options. Br J Ophthalmol 2017; 101: 130-95.
14. Baril C, Vianna JR, Shuba LM, Rafuse PE, Chauhan BC,
Nicolela MT. Rates of glaucomatous visual field change
after trabeculectomy. Br J Ophthalmol 2017; 101: 874-8.
15. Junoy Montolio FG, Müskens RPHM, Jansonius NM.
Influence of glaucoma surgery on visual function: a
clinical cohort study and meta-analysis. Acta Ophthalmol
2019; 97: 193-9.
16. Jiang L, Eaves S, Dhillon N, Ranjit P. Postoperative
outcomes following trabeculectomy and nonpenetrating
surgical procedures: a 5-year longitudinal study. Clin
Ophthalmol 2018; 12: 995-1002.
17. Rowe F. Perimetry Comparisons for Octopus G Top and
Dynamic Programmes versus Humphrey 24-2 SITA Fast
and SITA Standard Programmes. Ophthalmol Res An Int J
2013; 2: 24-42.
18. Chen PP, Budenz DL. The effects of cataract extraction on
the visual field of eyes with chronic open-angle glaucoma.
Am J Ophthalmol 1998; 125: 325-33.
19. Jonasson F, Damji KF, Arnarsson A, Sverrisson T, Wang
L, Sasaki H, et al. Prevalence of open-angle glaucoma in
Iceland: Reykjavik Eye Study. Eye (Lond) 2003; 17: 747-53.
20. Jonasson F, Arnarsson A, Eysteinsson T. The Reykjavik
Eye Study on Prevalence of Glaucoma in Iceland and
IdentifiedRisk Factors. Tombran-Tink J, Barnstable CJ,
Shield MB Mech Glaucomas Ophthalmol Res Humana
Press. 2008.
21. Ritch R, Schlötzer-Schrehardt U, Konstas AGP. Why is
glaucoma associated with exfoliation syndrome? Prog
Retin Eye Res 2003; 22: 253-75.
22. Arnarsson A, Damji KF, Sverrisson T, Sasaki H, Jonasson
F. Pseudoexfoliation in the Reykjavik Eye Study:
prevalence and related ophthalmological variables. Acta
Ophthalmol Scand 2007; 85: 822-7.
23. Forsius H. Prevalence of pseudoexfoliation of the lens in
Finns, Lapps, Icelanders, Eskimos, and Russians. Trans
Ophthalmol Soc U K 1980; 99: 296-8.
24. Heijl A, Bengtsson B, Hyman L, Leske MC, Early Manifest
Glaucoma Trial Group. Natural history of open-angle
glaucoma. Ophthalmology 2009; 116: 2271-6.
25. Desai MA, Lee RK. The medical and surgical management
of pseudoexfoliation glaucoma. Int Ophthalmol Clin 2008;
48: 95-113.
26. Konstas AG, Stewart WC, Stroman GA, Sine CS. Clinical
presentation and initial treatment patterns in patients
with exfoliation glaucoma versus primary open-angle
glaucoma. Ophthalmic Surg Lasers 1997; 28: 111-7.
27. King AJ, Stead RE, Rotchford AP. Treating patients pres-
enting with advanced glaucoma - should we reconsider
current practice? Br J Ophthalmol 2011; 95: 1185-92.
Heimildir